多粘菌素B
多粘菌素
医学
肺炎克雷伯菌
头孢他啶/阿维巴坦
内科学
头孢他啶
碳青霉烯
粘菌素
死亡率
抗生素
外科
重症监护医学
铜绿假单胞菌
微生物学
生物
细菌
遗传学
大肠杆菌
基因
生物化学
作者
Jingli Lü,Yani Ma,Zhe Cao,Baoling Zhu,Li Fan,Haiyang Meng
出处
期刊:Microbiology spectrum
[American Society for Microbiology]
日期:2024-11-21
卷期号:13 (1): e0177024-e0177024
被引量:3
标识
DOI:10.1128/spectrum.01770-24
摘要
ABSTRACT Although polymyxins are a suboptimal option for difficult-to-treat resistant infections, they are still preferred as the first-line treatment, especially in low- and middle-income countries. This study assesses the efficacy of ceftazidime-avibactam (CAZ-AVI) following polymyxin B failure in patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. We retrospectively reviewed cases of infections caused by CRKP in adults who received CAZ-AVI as salvage therapy. Clinical features and outcomes were described, and a logistic regression model was used to assess the risk factors associated with in-hospital crude mortality. One hundred and six patients were included in this study. The median age was 56 years. The most common infectious sites were lung. The patients received CAZ-AVI as salvage therapy for a median duration of 9 days following initial treatment with polymyxin B (median, 12.5 days). Also, 91 (85.8%) patients received CAZ-AVI combination therapy, and 34 (32.1%) patients received CAZ-AVI in combination with polymyxin B. The rate of in-hospital crude mortality was 25.5% (27/106), with the highest rate observed in patients treated with regimens containing polymyxin B (41.2%; 14/34). Therapeutic response was observed in 81 (76.4%) patients, with microbiological eradication achieved in 77.1% (74/96) of cases. Multivariable analysis identified that the length of intensive care unit stays, the sequential organ failure assessment (SOFA) score at CAZ-AVI withdrawal, and regimens containing polymyxin B were independently associated with in-hospital mortality, whereas the duration of CAZ-AVI treatment was independently associated with survival. CAZ-AVI salvage therapy demonstrated improved survival outcomes in patients who experienced failure with polymyxin B therapy. IMPORTANCE For patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) infections, published experience with salvage therapy is limited after the failure of polymyxin-based initial therapy. Here, we found that ceftazidime-avibactam salvage therapy for patients with CRKP infections offers benefit in mortality.
科研通智能强力驱动
Strongly Powered by AbleSci AI